Ukjent sin avatar

Human brain mechanisms of pain perception and regulation in health and disease

Denne beskriver det meste rundt hvordan forskjellige områder av hjernen aktiveres i smertetilstander.

Klikk for å få tilgang til NP%20-%20Apkarian%20-%202005%20-%20Human%20brain%20mechanisms%20of%20pain%20perception.pdf

 

Both primary somatosensory cortex (S1) and secondary somatosensory cortex (S2) are commonly activated in heat pain studies. Evidence suggests that the nociceptive input into these regions at least partially underlies the perception of sensory fea- tures of pain (Coghill et al., 1999; Peyron et al., 1999; Bushnell et al., 1999; Chen et al., 2002). Anterior cingu- late (ACC) and insular (IC) cortices, both components of the limbic system, are activated during the majority of PET or fMRI studies of heat pain, and these regions have been implicated in the affective processing of pain (Rainville et al., 1997; Tolle et al., 1999; Fulbright et al., 2001). Prefrontal cortical areas, as well as parietal association areas, are also sometimes activated by heat pain and may be related to cognitive variables, such as memory or stimulus evaluation (Coghill et al., 1999; Strigo et al., 2003). Motor and pre-motor cortical areas are on occasion activated by heat pain, but these activa- tions are less reliable, suggesting they may be related to pain epiphenomena, such as suppression of movement or actual pain-evoked movements themselves.

Subcortical activations are also observed, most notably in thalamus (Th), basal ganglia, and cerebellum (eTable 1). Fig. 1 illustrates the brain regions most com- monly reported activated in pain studies.

Utilizing similar methodology, rCBF responses to a l-opioid agonist, remifentanil, were com- pared to that elicited by a placebo (Petrovic et al., 2002a). The two effects overlapped in terms of rCBF increases in dorsal ACC, suggesting that this brain region may be in- volved in placebo effects. Perhaps more notably, placebo responders showed responses to remifentanil that were more prominent than non-responders. These data suggest that the placebo effect on pain responses may be mediated by inter-individual variations in the ability to activate this neurotransmitter system, as hypothesized by others (Amanzio and Benedetti, 1999).

Another recent study demonstrated that thermal stimulation in com- plex regional pain syndrome (CRPS) patients gives rise to activity that closely matches that observed in normal subjects. However, this pattern changes dramatically when the ongoing pain of CRPS is isolated, by com- paring brain activity before and after sympathetic blocks that reduce the ongoing CRPS pain but do not change the thermal stimulus pain (Apkarian et al., 2001). Thus, there is no compelling evidence that examining brain responses to experimental painful stimuli can predict the pattern of brain responses in chronic clinical pain states.

Thus, we can assert that brain activity for pain in chronic clinical conditions is different from brain activity for acute painful stimuli in normal subjects. We add the caution that this does not imply that all clinical pain conditions have a homo- geneous underlying brain activity pattern. On the con- trary, most likely the patterns involving different clinical conditions are unique but with the current avail- able data we cannot test this at a meta-analysis level.

The brain imaging studies reviewed here indicate the cortical and sub-cortical substrate that underlies pain perception. Instead of locating a singular ‘‘pain center’’ in the brain, neuroimaging studies identify a network of somatosensory (S1, S2, IC), limbic (IC, ACC) and asso- ciative (PFC) structures receiving parallel inputs from multiple nociceptive pathways (Fig. 1). In contrast to touch, pain invokes an early activation of S2 and IC that may play a prominent role in sensory-discriminative functions of pain. The strong affective-motivational character of pain is exemplified by the participation of regions of the cingulate gyrus. The intensity and affec- tive quality of perceived pain is the net result of the interaction between ascending nociceptive inputs and antinociceptive controls. Dysregulations in the function of these networks may underlie vulnerability factors for the development of chronic pain and comorbid conditions.

Our analysis, in- stead, suggests that chronic pain conditions may be a reflection of decreased sensory processing and enhanced emotional/cognitive processing.

 

Ukjent sin avatar

The conundrum of sensitization when recording from nociceptors

Mer fra Geoffrey Bove om nervogene betenneler og nocicepsjon. Denne forholder seg til nocicepsjon som oppstår under måling av nocicepsjon i studier, men har mange interessante poenger. Nevner at noceceptiv sensitering og kontinuerlig nociceptive aktivitet (ongoing activity(OA)) skjer spesielt i betennelsestilstander. Dette er grunnen til at alle med betennelsestilstander i kroppen bør senke betennelsesnivå for å få resultater av behandling.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854223/

When sensitized, nociceptors often exhibit activity in the absence of apparent or additional stimulation, called ongoing (or spontaneous) activity (OA).

We suggest that there are two types of OA, characterized by their rates. Very slow rates of ongoing activity (<0.2 Hz) are likely to arise from the receptive field and may indicate sensitization during the experiment. Faster rates are likely to arise from the nerve trunk, i.e. the neuritis, or the neuronal cell body.

A key feature of nociceptors is that they develop ongoing activity (OA) when they, or the structures they innervate, are injured or inflamed (Bessou and Perl, 1969Perl, 1976Perl, Kumazawa et al., 1976).

To locate RFs, especially in deep tissues, the structures must be stimulated noxiously. Thus, when a slowly conducting neuron is isolated, the peripheral structures from the distal thigh to the toes are stimulated noxiously using fingers or forceps. However, if a mechanical receptive field is not found, another neuron is isolated, and the search repeated. This typically takes dozens of searches over the course of the recording sessions, which in these experiments were 4–7 hours long. In our experiments it was clear that the noxious mechanical stimulus necessary to identify the RFs was in itself sufficient to cause inflammation.

Ongoing activity in sensory elements could be expected to impact the sensory modality of that element. Thus, OA in nociceptors could be expected to lead to the sensation of pain. However, the discharge rate that is necessary to reach perception remains unclear, and definitive studies have not been performed.

Using microneurography in humans, which is similar to the methods reported here, Konietzny et al., reported that electrically evoked nociceptor discharge rates as low at 0.5 Hz could evoke pain (Konietzny, Perl et al., 1981). Another human study reported that while nociceptor discharge under 0.2 Hz usually did not evoke pain, 0.4 Hz usually did (Van Hees and Gybels, 1981), consistent with a similar report (Van Hees and Gybels, 1972). These findings are in general consistent with our findings (Fig. 3). Although it thus remains unknown whether very slow levels of OA are significant for pain, any low rate will release neurotransmitters at their synapses in the spinal cord, which may be extensive due to the high degree of branching of primary afferent neurons to spinal cord neurons.

Ukjent sin avatar

The trigger point strikes … out!

En blog av Quinter som bedre forklarer det nevrologiske utgangspunktet for triggerpunkter, eller mer korrekt: ømme punkter og stramme muskler.

Basert på deres nye forklaringsmodell vil et problem (f.eks. betennelse) lenger inn på en sensorisk nerve sender betennelse (nevrogen betennelse) ut til muskelen, i tillegg til at motoriske og sympatiske (stress) signaler fra ryggmargen sendes ut til muskelen og gir en muskelspenning og twitchrespons vi kan se og kjenne med fingrene.

Ang. nevrogen betennelse så nevner wikipedia en studie på mus som viser at magnesium mangel, selv det som er innenfor «normalen» kan bidra til økt utskillelse av SP, som er en nevrogen betennelsesfaktor. http://en.wikipedia.org/wiki/Neurogenic_inflammation

***

But when I met the late Bob Elvey, he completely changed my way of thinking about these clinical problems. Bob’s mantra was that “muscles protect nerves.” He introduced me to the dynamics of the nervous system and I came to understand that peripheral nerves of the upper limb had evolved to be able to adapt to the various changes in limb position and length and that they were vulnerable at certain anatomical points along their course.

***

In brief, Geoff’s studies have had two major impacts on how we think about pain felt in muscles or other deep structures.

Firstly, he confirmed the presence of nociceptors with multiple receptive fields that branch within the nerve sheaths and extend to other deep tissues (nervi nervorum) [7]. The implication of this finding is that activity in a receptor in one structure such as the nerve sheath, could be perceived in another, such as the muscle.

Secondly, he showed that inflammation of nerves has profound effects on these same axons, the nociceptors to deep structures. These effects include ongoing activity and abnormal mechanical sensitivity [8, and others]. The implication of this finding is that this activity will be perceived by the brain in the area of the receptive fields mapped for the deep structure nociceptors, not in the area of the problem.

***

Figure 1. Proposed hypothesis for the development of focal muscle sensitivity and possible alteration in muscle texture with a proximal neural cause. Inflammation affecting a peripheral nerve (red spot) results in spontaneous and mechanically evoked afferent and efferent action potentials in small caliber sensory neurons innervating non-cutaneous structures, and decreased sympathetic discharge (-). These processes may cause reflex motor discharge sufficient to cause a palpable contraction (?), which combined with clinical phenomena associated with neurogenic inflammation (+), could explain the clinical phenomenon that has become known as a “trigger point.”

***

Ukjent sin avatar

Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia.

Denne nevner at mange smertelidelser har samme smertemekanisme som utgangspunkt: lavere nivå av intern smertedemping og central sensitering. De reagerer kraftigere på nococetive signaler som andre ikke reagerer så mye på.

http://www.ncbi.nlm.nih.gov/pubmed/21833699

Osteoarthritis (OA), low back pain (LBP), and fibromyalgia (FM) are common chronic pain disorders that occur frequently in the general population. They are a significant cause of dysfunction and disability. Why some of these chronic pain disorders remain localized to few body areas (OA and LBP), whereas others become widespread (FM) is unclear at this time. Genetic, environmental, and psychosocial factors likely play an important role. Although patients with OA, LBP, and FM frequently demonstrate abnormalities of muscles, ligaments, or joints, the severity of such changes is only poorly correlated with clinical pain. Importantly, many patients with these chronic pain disorders show signs of central sensitization and abnormal endogenous pain modulation. Nociceptive signaling is actively regulated by the central nervous system to allow adaptive responses after tissue injuries. Thus, abnormal processing of tonic peripheral tissue impulse input likely plays an important role in the pathogenesis of OA, LBP, or FM. Tonic and/or intense afferent nociceptive barrage can result in central sensitization that depends on facilitatory input from brainstem centers via descending pain pathways to the spinal cord. Abnormal endogenous control of these descending pathways can lead to excessive excitability of dorsal horn neurons of the spinal cord and pain. Ineffective endogenous pain control and central sensitization are important features of OA, LBP, and FM patients.

Ukjent sin avatar

Smertens nevrobiologi

Per Brodal, en av norges fremst nevrologer, skrev i 2005 en artikkel i Tidsskriftet om smertens nevrobiologi hvor han nevner mye av den nye forståelsen for smerte og referer til Melzack og Wall forskning.

http://tidsskriftet.no/article/1252875#reference-4

En annen innfallsvinkel fremhever smerteopplevelsens avhengighet av sammenhengen den opptrer i, av tidligere opplevelser og ikke minst av forventninger. Faktisk er smerteopplevelse ofte dårlig korrelert til grad av nociseptoraktivering (4). Smerteopplevelse kan derfor også forstås som en tolking av tilgjengelig informasjon (5).

Et hovedpoeng er at for å forstå smerte må man ta med den store betydningen av kognitive og emosjonelle forhold. Følgende spissformulering av Ramachandran & Blakeslee (5), basert på studier av pasienter med fantomsmerter, peker på betydningen av å søke etter mening bak smerteopplevelsen: «…pain is an opinion on the organism’s state of health rather than a mere reflexive response to an injury».

  • Smertesystemenes normale oppgaver er å beskytte og å gi instruks om hensiktsmessig atferd

  • Smertesystemenes plastisitet gjør dem sårbare for feiltilpasninger som kan medføre spontan smerte og abnorm reaksjon på trivielle stimuli

  • En del smertetilstander kan best forstås som hjernens tolking av kroppens tilstand på basis av ufullstendig og konfliktfylt informasjon

Ukjent sin avatar

noen studier om placeboeffekt ved kirurgi

Randomised Trial Support for Orthopaedic Surgical Procedures

Denne nevner at den samlede bevismengde for ortopediske inngrep viser at operasjoner ikke er bedre enn ikke-operativ behandling. Den nevner at kirurger forholder seg mindre (25%) til evidensbasert medisin enn andre leger (53%). Jeg legger merke til at kun 53% av avgjørelsene legene tar er evidensbaserte, den andre halvdelen av avgjørelser er det altså ikke evidens for.

The level of RCT support for common orthopaedic procedures compares unfavourably with other fields of medicine.

Empirical research has shown that healthcare decisions on medical wards are more likely to be based on randomised trial evidence (53%) [5] than those on surgical wards (24% to 26%) [6][8].

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057075/

Randomised Trial Support for Orthopaedic Surgical Procedures

Denne nevner at i 50% av de undersøkte kirurgiske inngrepene er det ikke evidens for at det er bedre enn placebo.

Placebo controlled trial is a powerful, feasible way of showing the efficacy of surgical procedures. The risks of adverse effects associated with the placebo are small. In half of the studies, the results provide evidence against continued use of the investigated surgical procedures. Without well designed placebo controlled trials of surgery, ineffective treatment may continue unchallenged.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029190/

Ukjent sin avatar

FORMIs Gule Flagg liste

Mange behandlere overser med vilje kostholdets forhold til smertetilstander. Av en eller annen grunn opplever de at mat spiller en svært lite rolle. Men dette er et blindfelt i deres persepsjonsevne som gjør at de ikke forholder seg til realitetene og snyter pasientene for mulig symptombedring.

Selv i de Nasjonale retningslinjene for korsryggsmerter sin liste over Gule Flagg (faktorer som bidrar til kroniske smertetilstander) står «problemer med mage» oppført. Dette i seg selv burde være nok til at ALLE behandlere som er i kontakt med smertepasienter setter seg inn i kostholdets betydning.

Gule flagg

Risikofaktorer (hovedsakelig psykososiale) for å utvikle mer langvarige ryggplager

• Arbeidsrelaterte problemer/sykmelding (bør tidsbegrenses)

• Emosjonelle problemer (f.eks depresjon og angst)

• Tilleggsymptomer i form av generaliserte smerter, hodepine, tretthet, svimmelhet og plager fra magen

• Pasienter med omfattende tidligere ryggplager og med nerverotaffeksjon

• Pessimistiske/negative holdninger/overbevisninger i forhold til smertene, f.eks uttalt engstelse for visse bevegelser og for å være i arbeid, og liten grad av forventning om å bli bra/komme tilbake i arbeid

Klikk for å få tilgang til Kortversjon.pdf

Ukjent sin avatar

Fructose Administration Increases Intraoperative Core Temperature by Augmenting Both Metabolic Rate and the Vasoconstriction Threshold

Mer om hvordan fruktose øker kroppvarme (termogenese). I denne er det snakk om å bruke det intravenøst for å unngå at pasienter blir kalde etter operasjoner. Det øker restitusjonsevnen etter operasjonen.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1473168/

Abstract

Background

We tested the hypothesis that intravenous fructose ameliorates intraoperative hypothermia both by increasing metabolic rate and the vasoconstriction threshold (triggering core temperature)

Methods

40 patients scheduled for open abdominal surgery were divided into two equal groups and randomly assigned to intravenous fructose infusion (0.5 g·kg−1·h−1 for 4 h, starting 3 h before induction of anesthesia and continuing for 4 hours) or an equal volume of saline. Each treatment group was subdivided: esophageal core temperature, thermoregulatory vasoconstriction, and plasma concentrations were determined in half, and oxygen consumption was determined in the remainder. Patients were monitored for 3 h after induction of anesthesia.

Results

Patient characteristics, anesthetic management, and circulatory data were similar in the four groups. Mean final core temperature (3 h after induction of anesthesia) was 35.7±0.4°C (mean ± SD) in the fructose group and 35.1±0.4°C in the saline group (P=0.001). The vasoconstriction threshold was greater in the fructose (36.2±0.3°C) than in the saline group (35.6±0.3°C; P<0.001). Oxygen consumption immediately before anesthesia induction in the fructose group (214±18 ml/min) was significantly greater than in the saline group (181±8 ml/min, P<0.001). Oxygen consumption was 4.0 L greater in the fructose patients during 3 hours of anesthesia; the predicted difference in mean-body temperature based only on the difference in metabolic rates was thus only 0.4°C. Epinephrine, norepinephrine, and angiotensin II concentrations, and plasma renin activity were similar in each treatment group.

Conclusions

Preoperative fructose infusion helped maintain normothermia by augmenting both metabolic heat production and increasing the vasoconstriction threshold.

Fructose is known to provoke the greatest thermogenesis among various carbohydrates.19,20 Fructose also provokes dietary-induced thermogenesis in awake healthy volunteers, and does so far better than glucose.15 We thus tested the hypothesis that intravenous fructose increases metabolic heat production in anesthetized humans. We also tested the hypothesis that fructose, like amino acids, increases the vasoconstriction threshold and thus has a thermoregulatory as well as metabolic contribution to maintaining perioperative normothermia.

CO2 production before infusion showed no significant difference between saline group (147+19 ml min−1) and fructose group (142+16 ml min−1) but increased significantly in the fructose group (201+26 ml min−1) just before induction of anesthesia, compared with the saline group (146+19 ml min−1)(p<0.001). This increased level was maintained for 135 min after induction of anesthesia.

Ukjent sin avatar

Comparison of thermogenic effect of fructose and glucose in normal humans.

Det er mange som advarer mot fruktose, og om det snakk om High Fructose Corn Sirup, eller et generelt overinntak av fruktose, så er det nok med det rette. Men det er ikke bare svarthvitt. Fruktose har en del positive egenskaper. Bla. at det øker termogenese, kroppens evne til å produsere varme istedet for energi (ATP). Dette henger sammen med evnen til å leve lenge (longevity) fordi da produserer mitokondriene mindre oksidative radikaler og mer CO2 istedet.

http://www.ncbi.nlm.nih.gov/pubmed/3521319/?ncbi_mmode=std

Abstract

After nutrient ingestion there is an increase in energy expenditure that has been referred to as dietary-induced thermogenesis. In the present study we have employed indirect calorimetry to compare the increment in energy expenditure after the ingestion of 75 g of glucose or fructose in 17 healthy volunteers. During the 4 h after glucose ingestion the plasma insulin concentration increased by 33 +/- 4 microU/ml and this was associated with a significant increase in carbohydrate oxidation and decrement in lipid oxidation. Energy expenditure increased by 0.08 +/- 0.01 kcal/min. When fructose was ingested, the plasma insulin concentration increased by only 8 +/- 2 microU/ml vs. glucose. Nonetheless, the increments in carbohydrate oxidation and decrement in lipid oxidation were significantly greater than with glucose. The increment in energy expenditure was also greater with fructose. When the mean increment in plasma insulin concentration after fructose was reproduced using the insulin clamp technique, the increase in carbohydrate oxidation and decrement in lipid oxidation were markedly reduced compared with the fructose-ingestion study; energy expenditure failed to increase above basal levels. To examine the role of the adrenergic nervous system in fructose-induced thermogenesis, fructose ingestion was also performed during beta-adrenergic blockade with propranolol. The increase in energy expenditure during fructose plus propranolol was lower than with fructose ingestion alone. These results indicate that the stimulation of thermogenesis after carbohydrate ingestion is related to an augmentation of cellular metabolism and is not dependent on an increase in the plasma insulin concentration per se.